RxDoctor Payments Data

Christopher Dibello, MD

Pulmonary Disease · New Smyrna Beach, FLNPI 1487875977

Payments from drug & device makers

$33,335in general payments, 2019–2025

Across 630 payments — averaging $52.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$19K
  • Intuitive Surgical$4K
  • AstraZeneca$2K
  • GSK$2K
  • Regeneron Healthcare Solutions, Inc.$742
  • Philips North America LLC$578
  • plus $4K from 43 others

What the payments were for

  • Speaking & faculty fees$16,22549%
  • Travel & lodging$2,3777%
  • Food & beverage$11,40534%
  • Education$3,32810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,335 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$977,453
Medicare patients
1,801
Services billed
45,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,204$964,037
Breztri AerosphereBudesonide/Glycopyr/Formoterol261$208,885
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr352$196,048
Stiolto RespimatTiotropium Br/Olodaterol Hcl182$128,960
OfevNintedanib Esylate15$115,519
Breo ElliptaFluticasone/Vilanterol191$100,868
Spiriva RespimatTiotropium Bromide103$78,940
EliquisApixaban103$71,067
XolairOmalizumab13$64,524
Dupixent PenDupilumab12$40,480
Albuterol Sulfate HfaAlbuterol Sulfate1,280$30,966
SymbicortBudesonide/Formoterol Fumarate80$30,747
Fluticasone-SalmeterolFluticasone Propion/Salmeterol224$29,810
XareltoRivaroxaban34$24,987
Azelastine Hcl765$20,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$1,881$1,279,2561,813 claims
Boehringer IngelheimStiolto Respimat, Ofev, Spiriva Respimat, Combivent Respimat, Jardiance$19,145$355,852345 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$2,319$253,614369 claims
PfizerEliquis$14$71,067103 claims
Johnson & JohnsonXarelto$407$24,98734 claims
MerckJanumet$84$7,99612 claims
AbbVieLinzess$210$6,99813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in New Smyrna Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →